New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis

Apr 16, 2010

Results from a multinational phase II study presented today at the International Liver Congress 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH - the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine (ALT) and aspartate aminotransferases (AST), hepatic enzymes that indicate cell damage.

GS-9450, a potent inhibitor of caspases-8, -9 and -1, the intra-cellular proteins that initiate programmed cell death (or cell suicide, also known as apoptosis) in damaged cells, is a potential new treatment option for patients with NASH - a disease characterised by fat build-up in with subsequent inflammation resulting in accumulation of (fibrosis), cirrhosis and eventual .

Professor Fabio Marra of the EASL scientific committee commented: "It is encouraging to see that GS-9450-associated reduction of apoptosis and cell damage seen in animal models has translated to a significant patient population, and seems to be consistent with a good tolerability profile in patients from a variety of countries. Further studies are needed to evaluate the action of this therapy on histology and to confirm the drug's efficacy and safety in larger patient populations."

In this double-blind, parallel-group study, patients (n=124, principally male, mean age 45 years, with (BMI) of >30kg/m2) with biopsy-proven NASH were randomised to receive 1, 5, 10 or 40mg GS-9450 or placebo once daily for 4 weeks. After 4 weeks on treatment, patients in the 40mg treatment group experienced the greatest reduction in ALT and AST levels.

At week four, linear regression of ALT versus GS-9450 dose was highly significant (p<0.0001) with 35% achieving alt levels within the normal range (7-56 u/l ) compared to 0% at study baseline, and 48% achieving normal levels of ast (5-40 u/l1) compared to 20% at baseline. placebo treatment showed no meaningful change for alt or ast.

Additionally, the on-treatment measure of cytokeratin-18 caspase cleavage fragments (proteins that act as markers for liver cell death) declined in the 10 and 40mg dose groups (median baseline and week four values respectively were 540 and 445 U/L in the 10mg group and 562 and 386 U/L in the 40mg group), although no dose-related response was seen.

Explore further: Poland suffers first cases of African swine fever in pigs

More information:
References:

1Ratzui V. et al., Safety, Tolerability and preliminary activity of GS-9450, a selective caspase inhibitor, in patients with non-alcoholic steatohepatitis (NASH). Abstract presented at The International Liver Congress 2010

2Liver Blood Tests. Available at www.medicinenet.com/liver_blood_tests/page2.htm accessed 08.04.10

Provided by European Association for the Study of the Liver

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Noninvasive ways to assess liver disease

Feb 02, 2008

Two new studies examine non-invasive ways to determine liver fibrosis and cirrhosis. An enhanced version of the Original European Liver Fibrosis panel was found to have good diagnostic accuracy for fibrosis in patients with ...

New data emerges on liver transplant survival rates

Nov 25, 2009

Researchers at the University of Miami School of Medicine compared the outcomes of cirrhotic patients who underwent liver transplants for nonalcoholic steatohepatitis (NASH) versus alcoholic liver disease (ETOH) and found ...

Recommended for you

Experts call for stepped-up hepatitis battle

30 minutes ago

The world can beat the cancer-causing disease hepatitis if it raises its game, but treatment programmes need to go hand in hand with those tackling the likes of HIV, experts said Thursday.

User comments : 0